The Diabetes Phase 3 clinical trial was a Multi-centric, Prospective, Randomized, Double- blind Study to Evaluate the Safety and Efficacy of Saroglitazar Mg 2 mg and 4 mg as compared to Pioglitazone 30 mg in patients with type 2 diabetes. The Phase 3 trial conducted in 1140 type 2 diabetes patients for a total of 56 weeks met the primary end-points (CTRI/2015/09/006203). The primary outcome measure was the change from baseline in glycosylated hemoglobin (HbAlc) for Saroglitazar 4 mg, 2 mg and Pioglitazone 30 mg at 24 weeks. The secondary outcome measures included the change from baseline in fasting plasma glucose, 2 hour postprandial plasma glucose, lipid profile, Triglyceride (TG) cholesterol, Low density lipoprotein (LDL) cholesterol, Very low density lipoprotein (VLDL) cholesterol, High density lipoprotein (LDL) cholesterol, Total cholesterol (TC) cholesterol, Non HDL cholesterol, Apolipoprotein (Apo) Al and Apo B between Saroglitazar (4 mg, 2 mg) and Pioglitazone (30 mg) treatment at Week 12, 24 and 56.
In Phase [II diabetes trial, at 24 weeks, HbAlc was reduced by 1.38 g/dL with Saroglitazar 2 mg, 1.47 g/dL with Saroglitazar 4 mg and 1.41 g/dL with Pioglitazone 30 mg. At 56 weeks, HbAlc reduced by 1.34 g/dL with Saroglitazar 2 mg, 1.49 g/dL with Saroglitazar 4 mg and 1.47 g/dL with Pioglitazone 30 mg. Saroglitazar did not cause hypoglycemia or weight gain in this trial.
“Insulin resistance is one of the primary causes ofdiabetes and there is a huge unmet medical need for a safe and effective insulin sensitizer. Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from Type 2 diabetes mellitus. With the increasing cases of diabetes in India, the need to strengthen diabetes management and help patients control their blood sugar levels is of critical importance.” mentioned Pankaj Patel, Chairman, Zydus Group.
Saroglitazar (LipaglynTM), is a novel PPARa/y agonist having predominant PPAR alpha activity. The recommended dose of LipaglynTM is 4 mg once-a—day. LipaglynTM is a prescription drug and should be taken under guidance of a registered medical practitioner. LipalgynTM was first launched in India during September 2013. Over the last several years, more than 1 Million patients have been treated with LipaglynTM in India for management of Hypertriglyceridemia and Diabetic Dyslipidemia, and data has been presented at several scientific and medical conferences.
Cadila Healthcare Ltd is currently trading at Rs259.95 down by Rs0.5 or 0.19% from its previous closing of Rs260.45 on the BSE.